Daiva Radzišauskienė1, Monika Vitkauskaitė2, Karolina Žvinytė2, Rūta Mameniškienė3. 1. Department of Infectious Diseases and Dermatovenerology, Vilnius University, Vilnius, Lithuania. 2. Faculty of Medicine, Vilnius University, Vilnius, Lithuania. 3. Department of Neurology and Neurosurgery, Vilnius University, Vilnius, Lithuania.
Abstract
OBJECTIVES: Not much is known about influenza-associated neurological complications. We aimed to describe the case series of hospitalized patients who were confirmed with influenza A and presented with neurological symptoms in order to capture the broad spectrum of influenza clinical manifestation and suggest including influenza diagnostic in some neurological conditions. MATERIALS AND METHODS: The inclusion criteria were age ≥ 18 and laboratory-confirmed influenza presenting with neurological symptoms. Influenza-associated neurological complication was described as a development of neurological symptom with no other origin. The outcomes were classified into 5 categories: 1. recovery with no significant disability; 2. minor disability (able to manage on their own); 3. moderate disability (requiring some help but able to walk without assistance); 4. severe disability (unable to walk without assistance and perform daily activities); 5. death. RESULTS: In total, 12 patients (five women and seven men) were enrolled, with age range 18-71 years old. Neurological complications of pandemic A(H1 N1 )2009pdm influenza developed in seven out of 69 (10.1%) hospitalized patients. The most common neurological complication was encephalopathy. Neurological complications developed in two out of 24 (8.3%) hospitalized patients during postpandemic (H1 N1 )V period. One patient presented with encephalopathy, another with meningoencephalitis. During the 2018 influenza season, there was one patient who has developed influenza A neurological complications. Overall, two out of 104 (1.9%) influenza A patients developed influenza-associated neurological complications in 2019. CONCLUSIONS: Every patient with unexplained neurological symptoms and signs similar to aseptic and septic meningitis/encephalitis has to be tested for influenza virus during epidemics and pandemics.
OBJECTIVES: Not much is known about influenza-associated neurological complications. We aimed to describe the case series of hospitalized patients who were confirmed with influenza A and presented with neurological symptoms in order to capture the broad spectrum of influenza clinical manifestation and suggest including influenza diagnostic in some neurological conditions. MATERIALS AND METHODS: The inclusion criteria were age ≥ 18 and laboratory-confirmed influenza presenting with neurological symptoms. Influenza-associated neurological complication was described as a development of neurological symptom with no other origin. The outcomes were classified into 5 categories: 1. recovery with no significant disability; 2. minor disability (able to manage on their own); 3. moderate disability (requiring some help but able to walk without assistance); 4. severe disability (unable to walk without assistance and perform daily activities); 5. death. RESULTS: In total, 12 patients (five women and seven men) were enrolled, with age range 18-71 years old. Neurological complications of pandemic A(H1 N1 )2009pdm influenza developed in seven out of 69 (10.1%) hospitalized patients. The most common neurological complication was encephalopathy. Neurological complications developed in two out of 24 (8.3%) hospitalized patients during postpandemic (H1 N1 )V period. One patient presented with encephalopathy, another with meningoencephalitis. During the 2018 influenza season, there was one patient who has developed influenza A neurological complications. Overall, two out of 104 (1.9%) influenza A patients developed influenza-associated neurological complications in 2019. CONCLUSIONS: Every patient with unexplained neurological symptoms and signs similar to aseptic and septic meningitis/encephalitis has to be tested for influenza virus during epidemics and pandemics.
Authors: Ting Lei; Kam-Leung Siu; Kin-Hang Kok; Kwok-Hung Chan; Eric Y T Chan; Ivan F N Hung; Kelvin K W To; Patrick C K Li; Jie Zhou; Bo-Jian Zheng; Kwok-Yung Yuen; Ming Wang; Dong-Yan Jin Journal: Vaccine Date: 2012-02-16 Impact factor: 3.641
Authors: Nelson Lee; Paul K S Chan; Grace C Y Lui; Bonnie C K Wong; Winnie W Y Sin; Kin-Wing Choi; Rity Y K Wong; Elaine L Y Lee; Apple C M Yeung; Karry L K Ngai; Martin C W Chan; Raymond W M Lai; Alex W Y Yu; David S C Hui Journal: J Infect Dis Date: 2011-06-15 Impact factor: 5.226
Authors: Anu Goenka; Benedict D Michael; Elizabeth Ledger; Ian J Hart; Michael Absoud; Gabriel Chow; James Lilleker; Michael Lunn; David McKee; Deirdre Peake; Karen Pysden; Mark Roberts; Enitan D Carrol; Ming Lim; Shivaram Avula; Tom Solomon; Rachel Kneen Journal: Clin Infect Dis Date: 2013-12-18 Impact factor: 9.079
Authors: Wouter J Meijer; Francisca H H Linn; Anne M J Wensing; Helen L Leavis; Debby van Riel; Corine H GeurtsvanKessel; Mike P Wattjes; Jean-Luc Murk Journal: JMM Case Rep Date: 2016-12-19